Small-molecule modulators of the OX40OX40 ligand co-stimulatory proteinprotein interaction

British Journal of Pharmacology

Volumn 171, Issue 21, 2014, Pages 4955-4969

  Song, Yun ^a   Margolles Clark, Emilio ^a   Bayer, Allison ^a,b   Buchwald, Peter ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CD4 ANTIGEN; CHLORAZOL VIOLET N; DIRECT BLACK 36; DIRECT BLUE 15; DIRECT BLUE 71; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; L SELECTIN; OX40 LIGAND; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ARTICLE; CELL ASSAY; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; EX VIVO STUDY; HUMAN; HUMAN CELL; IC50; IMMUNOMODULATION; INHIBITION KINETICS; LIGAND BINDING; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN DETERMINATION; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; TH9 CELL; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CD4+ T LYMPHOCYTE; CELL CULTURE; GENETICS; HEK293 CELL LINE; METABOLISM; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELLS, CULTURED; FORKHEAD TRANSCRIPTION FACTORS; HEK293 CELLS; HUMANS; MICE, TRANSGENIC; OX40 LIGAND; RECEPTORS, OX40;

EID: 84919360941     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12819     Document Type: Article

References (53)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic receptors. Br J Pharmacol 170: 1676-1703.
2. Ark in MR, Wells JA (2004). Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 3: 301-317.
3. Black JW, Leff J (1983). Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220: 141-162.
4. Bodor N, Buchwald P (2012) Retrometabolic Drug Design and Targeting, 1st edn. Wiley: Hoboken, NJ.
5. Bresson D, Fousteri G, Manenkova Y, Croft M, von Herrath M (2011). Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment. J Autoimmun 37: 342-351.
6. Buchwald P (2010). Small-mol ecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations. IUBMB Life 62: 724-731.
7. Chen M, Xiao X, Demirci G, Li XC (2008). OX40 controls islet allograft tolerance in CD154 deficient mice by regulating FOXP3+ Tregs. Transplantation 85: 1659-1662.
8. Cheng AC, Coleman RG, Smyth KT, Cao Q, Soulard P, Caffrey D R et al. (2007). Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol 25: 71-75.
9. Cochran AG (2000). Antagonists of protein-protein interactions. Chem Biol 7: R85-R94.
10. Croft M (2010). Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol 28: 57-78.
11. Croft M, So T, Duan W, Soroosh P (2009). The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev 229: 173-191.
12. Croft M, Benedict CA, Ware CF (2013). Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov 12: 147-168.
13. Del Castillo J, Katz B (1957). Interaction at end-plate receptors between different choline derivatives. Proc R Soc Lond B Biol Sci 146: 369-381.
14. Dollins CM, Nair S, Boczkowski D, Lee J, Layzer JM, Gilboa E et al. (2008). Assembling OX40 aptamers on a molecular scaffold to create a receptor-Activating aptamer. Chem Biol 15: 675-682.
15. Duan W, So T, Croft M (2008). Antagonism of airway tolerance by endotoxin/lipopolysaccharide through promoting OX40L and suppressing antigen-specific Foxp3+ T regulatory cells. J Immunol 181: 8650-8659.
16. Ganesan L, Margolles-Clark E, Song Y, Buchwald P (2011). The food colorant erythrosine is a promiscuous protein-protein interaction inhibitor. Biochem Pharmacol 81: 810-818.
17. Griseri T, Asquith M, Thompson C, Powrie F (2010). OX40 is required for regulatory T cell-mediated control of colitis. J Exp Med 207: 699-709.
18. He MM, Smith AS, Oslob JD, Flanagan WM, Braisted AC, Whitty A et al. (2005). Small-molecule inhibition of TNF. Science 310: 1022-1025.
19. Hopkins AL, Groom CR (2002). The druggable genome. Nat Rev Drug Discov 1: 727-730.
20. Ishii N, T akahashi T, Soroosh P, Sugamura K (2010). OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology. Adv Immunol 105: 63-98.
21. Ito T,Wang YH,Duramad O,Hanabuchi S,Perng OA,Gilliet M,et al. 2006 OX40 ligand shuts down IL-10-producing regulatory T cells Proc Natl Acad Sci USA 103, 13138-13143.
22. Jenkinson DH (2003). Classical approaches to the study of drug-receptor interactions. In: Foreman JC, Johansen T (eds). Textbook of Receptor Pharmacology, 2nd edn. CRC Press: Boca Raton, FL, pp. 3-80.
23. Kenakin TP (2006). A Pharmacology Primer: Theory, Applications, and Methods, 2nd edn. Academic Press: San Diego, CA.
24. Kinnear G, Wood KJ, Fallah-Arani F, Jones ND (2013). A diametric role for OX40 in the response of effector/memory CD4+ T cells and regulatory T cells to alloantigen. J Imm unol 191: 1465-1475.
25. Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, Shu S (2000). Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res 60: 5514-5521.
26. Kroemer A, Xiao X, Vu MD, Gao W, Minamimura K, Chen M et al. (2007). OX40 controls functionally different T cell subsets and their resistance to depletion t herapy. J Immunol 179: 5584-5591.
27. Margolles-Clark E, Jacques-Silva MC, Ganesan L, Umland O, Kenyon NS, Ricordi C et al. (2009a ). Suramin inhibits the CD40-CD154 costimulatory interaction: a possible mechanism for immunosuppressive effects. Biochem Pharmacol 77: 1236-1245.
28. Margolles-Clark E, Umland O, Kenyon NS, Ricordi C, Buchwald P (2009b ). Small molecule costimulatory blockade: organic dye inhibitors of the CD40-CD154 interaction. J Mol Med 87: 1133-1143.
29. Margolles-Clark E, Kenyon NS, Ricordi C, Buchwald P (2010). Effective and specif ic inhibition of the CD40-CD154 costimulatory interaction by a naphthalenesulphonic acid derivative. Chem Biol Drug Des 76: 305-313.
30. Milroy LG, Brunsveld L, Ottmann C (2013). Stabilization and inhibition of protein-protein interactions: the 14-3-3 case study. ACS Chem Biol 8: 27-35.
31. Ottmann C (2013). Small-molecule modulators of 14-3-3 protein-protein interactions. Bioorg Med Chem 21: 4058-4062.
32. Pakala SV, Bansal-Pakala P, Halteman BS, Croft M (2004). Prevention of diabetes in NOD mice at a late stage by targeting OX40/OX40 ligand interactions. Eur J Immunol 34: 3039-3046.
33. Pawson AJ, Sh arman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA, Southan C, Spedding M, Yu W, Harmar AJ; NC-IUPHAR. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an exper t-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res 42 (Database Issue): D1098-106.
34. Piconese S, Valzasina B, Colombo MP (2008). OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 205: 825-839.
35. Redmond WL, Ruby CE, Weinberg AD (2009). The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit Rev Immunol 29: 187-201.
36. Rose R, Erdmann S, Bovens S, Wolf A, Rose M, Hennig S et al. (2010). Identification and structure of small-molecule stabilizers of 14-3-3 protein-protein interactions. Angew Chem Int Ed Engl 49: 4 129-4132.
37. Ruby CE, Yates MA, Hirschhorn-Cymerman D, Chlebeck P, Wolchok JD, Houghton AN et al. (2009). Cutting edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. J Immunol 183: 4853-4857.
38. Sheridan C (2013). Industry pursues co-stimulatory receptor immunomodulators to treat cancer. Nat Biotechnol 31: 181-183.
39. Silvian LF, Friedman JE, Strauch K , Cachero TG, Day ES, Qian F et al. (2011). Small molecule inhibition of the TNF family cytokine CD40 ligand through a subunit fracture mechanism. ACS Chem Biol 6: 636-647.
40. Smith RD, Hu L, Falkner JA, Benson ML, Nerothin JP, Carlson HA (2006). Exploring protein-ligand recognition with binding MOAD. J Mol Graph Model 24: 414-425.
41. So T, Croft M (200 7). Cutting edge: OX40 inhibits TGF-beta-And antigen-driven conversion of naive CD4 T cells into CD25+ Foxp3+ T cells. J Immunol 179: 1427-1430.
42. Sugamura K,Ishii N,Weinberg AD 2004 Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40 Nat Rev Immunol 4 420-431.
43. Takeda I, Ine S, Killeen N, Ndhlovu LC, Murata K, Satomi S et al. (2004). Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J Immunol 172: 3580-3589.
44. Tansey MG, Szymkowski DE (2009). The TNF superfamily in 2009: new pathways, new indications, and new drugs. Drug Discov Today 14: 1082-1088.
45. Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD, Colombo MP (2005). Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 105: 2845-2851.
46. Vu MD, Xiao X, Gao W, Degauque N, Chen M, Kroemer A et al. (2007). OX40 costimulation turns off Foxp3+ Tregs. Blood 110: 2501-2510.
47. Wang G, Wang X, Yu H, Wei S, Williams N, Holmes DL et al. (2013). Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. Nat Chem Biol 9: 84-89.
48. Weinberg AD, Rivera MM, Prell R, Morris A, Ramstad T, Vetto JT et al. (2000). Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 164: 2160-2169.
49. Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD (2011). Science gone translational: the OX40 agonist story. Immunol Rev 244: 218-231.
50. Wells JA, McClendon CL (2007). Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450: 1001-1009.
51. Whitty A, Kumaravel G (2006).Between a rock and a hard place? Nat Chem Biol 2: 112-118.
52. Xiao X, Balasubramanian S, Liu W, Chu X, Wang H, Taparowsky EJ et al. (2012). OX40 signaling favors the induction of T(H)9 cells and airway inflammation. Nat Immunol 13: 981-990.
53. Yao S, Zhu Y, Chen L (2013). Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov 12: 130-146.